Yüklüyor......

ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics

Dolutegravir (DTG) is a potent integrase inhibitor of human immunodeficiency virus. Because DTG is a substrate of the efflux transporter ABCG2 and ABCG2 is highly polymorphic, we asked whether dose adjustment of DTG is needed for ABCG2-deficient individuals. Using Abcg2-null mice, the current work i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Pharmacol Exp Ther
Asıl Yazarlar: Zhu, Junjie, Tian, Xin, Shehu, Amina I., McMahon, Deborah K., Ma, Xiaochao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The American Society for Pharmacology and Experimental Therapeutics 2020
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292963/
https://ncbi.nlm.nih.gov/pubmed/32303561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.264424
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!